Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C20H30O5.2C6H13N2O2.Mg |
| Molecular Weight | 1015.5626 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 10 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].NCCCC[C@H](N)C([O-])=O.NCCCC[C@H](N)C([O-])=O.CC[C@H](O)\C=C\C=C/C[C@H](O)\C=C\C=C\C=C/[C@H](O)CCCC(O)=O.CC[C@H](O)\C=C\C=C/C[C@H](O)\C=C\C=C\C=C/[C@H](O)CCCC(O)=O
InChI
InChIKey=SDQHYEFWEQOSBL-DXJCSENFSA-L
InChI=1S/2C20H30O5.2C6H14N2O2.Mg/c2*1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25;2*7-4-2-1-3-5(8)6(9)10;/h2*3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25);2*5H,1-4,7-8H2,(H,9,10);/q;;;;+2/p-2/b2*4-3+,9-5-,11-8+,12-6+,13-7-;;;/t2*17-,18+,19-;2*5-;/m0000./s1
| Molecular Formula | C6H13N2O2 |
| Molecular Weight | 145.1796 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H30O5 |
| Molecular Weight | 350.4492 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 5 |
| Optical Activity | UNSPECIFIED |
Resolvin E1 (RvE1 or RX-10001) is a trihydroxy eicosapentaenoic acid metabolite that has a role as an anti-inflammatory agent and a human xenobiotic metabolite. This compound binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR23 on monocyte/macrophages. Resolvin E1 has been shown to reverse experimental periodontitis and dysbiosis in rats. Furthermore, in a murine model of Alzheimer’s disease, Resolvin E1 (in combination with lipoxin A4) decreased neuroinflammation. Resolvin E1 was also suggested as a potential therapeutic target for psoriasis. A phase I clinical trial to test drug safety in healthy volunteers has been completed in 2009.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. | 2005 Mar 7 |
|
| Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. | 2007 Mar 15 |
|
| Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. | 2010 May |
|
| Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. | 2010 Oct |
|
| Resolvins: natural agonists for resolution of pulmonary inflammation. | 2011 Jan |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:21:53 GMT 2023
by
admin
on
Sat Dec 16 19:21:53 GMT 2023
|
| Record UNII |
AH6WA47YR3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
826721
Created by
admin on Sat Dec 16 19:21:53 GMT 2023 , Edited by admin on Sat Dec 16 19:21:53 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AH6WA47YR3
Created by
admin on Sat Dec 16 19:21:53 GMT 2023 , Edited by admin on Sat Dec 16 19:21:53 GMT 2023
|
PRIMARY | |||
|
166451421
Created by
admin on Sat Dec 16 19:21:53 GMT 2023 , Edited by admin on Sat Dec 16 19:21:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|